Exelixis Stock News

With the Nasdaq Composite down as much as 38% from its peak, these highly innovative companies are ripe for the picking.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Both drugmakers have outperformed the market in the past year.

EXEL vs. TECH: Which Stock Is the Better Value Option?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

EXEL vs. TECH: Which Stock Is the Better Value Option?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The mean of analysts' price targets for Exelixis (EXEL) points to a 74% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts

These stocks have low-to-no debt, and analysts see tons of upside.

These stocks have low-to-no debt, and analysts see tons of upside.

Upgrades According to Jefferies, the prior rating for Target Corp (NYSE:TGT) was changed from Hold to Buy. Target earned $0.39 in the second quarter, compared to $3.64 in the year-ago quarter. The cur

Cheap stocks have the ability to generate enormous, long-term profits for investors.

EXEL vs. TECH: Which Stock Is the Better Value Option?